Indication
Gastric Adenocarcinoma
Aliases
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
27 clinical trials
44 products
19 drugs
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORSStatus: Terminated, Estimated PCD: 2023-11-28
Product
PF-07062119Product
Anti-PD1Product
Anti-VEGFProduct
5-FluorouracilProduct
LeucovorinClinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-24
Product
RamucirumabProduct
PEGPH20Product
LinagliptinProduct
AtezolizumabProduct
CobimetinibProduct
OxaliplatinProduct
PaclitaxelProduct
BL-8040Product
CisplatinProduct
TiragolumabProduct
SHR-8068Clinical trial
A Randomized, Open, Multicenter Phase II Clinical Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the First-line Treatment of Advanced Gastric and Esophageal CancerStatus: Recruiting, Estimated PCD: 2025-02-01
Product
AdebrelimabClinical trial
Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-23
Product
Tusamitamab ravtansineClinical trial
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-02-07
Product
BI-1607Clinical trial
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary TumorsStatus: Completed, Estimated PCD: 2021-08-20
Product
everolimusProduct
docetaxelProduct
pembrolizumabProduct
ibrutinibProduct
paclitaxelProduct
cetuximabClinical trial
A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-30
Product
LenvatinibProduct
PembrolizumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideProduct
Neoantigen Peptide VaccineClinical trial
A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel ObstructionStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
DocetaxelDrug
FOLFOXIRIDrug
5-FUClinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797Drug
BotensilimabProduct
BalstilimabDrug
TiragolumabClinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 StudyStatus: Recruiting, Estimated PCD: 2024-07-31
Product
Trifluridine and TipiracilClinical trial
Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-04-01
Product
OlaparibClinical trial
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory StudyStatus: Completed, Estimated PCD: 2023-03-01
Clinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-09-09
Drug
zolbetuximabDrug
placeboDrug
oxaliplatinDrug
mFOLFOX6Drug
fluorouracilClinical trial
Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
Nimotuzumab + PaclitaxelProduct
Placebo + PaclitaxelClinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)Status: Recruiting, Estimated PCD: 2027-02-22
Product
ZongertinibProduct
Trastuzumab deruxtecanProduct
Trastuzumab emtansineClinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-11-08
Drug
mFOLFOXIRIDrug
T-VECClinical trial
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).Status: Not yet recruiting, Estimated PCD: 2025-08-31
Product
nal-IRIProduct
Trifluridine + TipiracilClinical trial
A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive CytologyStatus: Active (not recruiting), Estimated PCD: 2028-10-30
Clinical trial
An International, Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma After Radical GastrectomyStatus: Recruiting, Estimated PCD: 2026-03-31
Product
JS001/PlaceboProduct
JS001Clinical trial
A Prospective, Single-arm Clinical Trial of Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
EnvafolimabDrug
S1Clinical trial
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)Status: Recruiting, Estimated PCD: 2028-03-31
Drug
AN0025Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
BerzosertibDrug
IrinotecanClinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-10-25
Drug
letrozoleDrug
Trastuzumab